SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities of $2.27M in Q1 FY2026
Q1 FY2026 other current liabilities was $2.27M.
Context
- Other current liabilities amounted to 0.9% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.89M USD
- Year-over-year change
- —
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.89M | — |
Other Current Liabilities vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Other current liabilities amounts to 0.9% of total assets for SGP, versus a peer median of 7.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.42B USD | +31.7% | +25.7% | 10.3% | |
| Sep 2026 | $1.4B USD | +12.2% | -6.1% | 4.5% | |
| Jun 2026 | $83.19M USD | +3482.7% | +28.8% | 9.0% | |
| Mar 2026 | CHF 35.44M CHF | +137.3% | +32449.2% | 14.6% | |
| Apr 2026 | $32.96M USD | +26.0% | +16.3% | 7.3% | |
| Mar 2026 | $28.45M USD | — | — | 3.9% | |
| Mar 2026 | $18.75M USD | — | +14.2% | 6.2% | |
| Mar 2026 | $8.89M USD | +58.9% | +20.6% | 3.1% | |
| Mar 2026 | $8.83M USD | +72.3% | -6.2% | 8.0% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $2.27M USD | — | — | 0.9% |
| Peer median (excluding SGP) | — | +58.9% | +18.4% | 7.3% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.